Efficient and Effective Use of Exfoliative Markers
|
|
- Eugene Fisher
- 5 years ago
- Views:
Transcription
1 Innovations in Urologic Oncology: Bladder Cancer Efficient and Effective Use of Exfoliative Markers Jared M Whitson, MD April 9 th, 2010, CA URINARY TUMOR MARKERS Future Directions Urinary Tumor Markers Hemoglobin Dipstick Hemoglobin Dipstick Point-of-Care Urinary Cytology BTA-STAT / BTA-TRAK NMP-22 ImmunoCyt Detects hematuria, hemoglobinuria, myoglobinuria 25 cents False positives occur for any GU source not due to bladder cancer UroVysion Follow-up with microscopic evaluation of urine Positive test 2 RBC s/hpf on 2/3 specimen 1
2 Urinary Cytology BTA-STAT / BTA-TRAK Point-of-Care (BTA-STAT) Send out ELISA (BTA-TRAK) >14 U/mL positive Send out to cytopathologist Detects Human Complement H related protein Cost around $60-$100 $10-$15 BTA STAT / $175 BTA-TRAK Often equivocal, atypical, or suspicious Patients already diagnosed with bladder cancer Used in conjunction with cystoscopy Equivocal or Atypical frequent during BCG Not for screening, patients with signs of active infections, patients who have received BCG NMP-22 ImmunoCyt Point of Care (BladderCheck) Send out ELISA (NMP22) >10 U/mL positive Nuclear Matrix Apparatus Protein Send out conjunction cytology Carcinoembryonic Antigen (CEA) and 2 bladder cancer specific mucins Single red or green cell positive $10-$30 (BladderCheck) / $125-$150 (NMP22) Both initial diagnosis patients risk factors or symptoms and monitoring $130-$385 patients known bladder cancer along with cystoscopy Not for screening, or use in patients catheters or stents, or after cystectomy 2
3 UroVysion Comparison of Markers (2006) Send out to specialized lab Fluorescence in situ hybridization detects aneuploidy chromosomes 3,7, and 17 and loss of 9p21 locus 4 cells gains 3,7,17 or 12 cells loss 9p21 $475-$700 in patients with hematuria or monitoring in patients with known bladder cancer Marker Mean Sensitivity (range) Mean Specificity (range) Hgb Dipstick 71% (47%-93%) 67% (51%-84%) Cytology 48% (28%-76%) 96% (81%-100%) BTA-STAT 69% (53%-89%) 74% (54%-93%) BTA-TRAK 62% (17%-78%) 74% (51%-95%) NMP22 68% (31%-92%) 74% (5%-94%) ImmunoCyt 58% (39%-86%) 79% (73%-84%) UroVysion 77% (73%-81%) 98% (96%-100%) Not for use when patient has known untreated tumor Konety Urol Onc 2006 Comparison (2010) Marker Patients Sensitivity (95% CI) Specificity (95% CI) Cytology 22,260 44% (38%-51%) 96% (94%-98%) NMP22 13,885 68% (62%-74%) 79% (74%-84%) ImmunoCyt 4,199 84% (77%-91%) 75% (68%-83%) UroVysion 3,321 76% (65%-84%) 85% (78%-92%) Public Health and Economic Impact Urinary Tumor Markers SCREENING Future Directions Mowatt Health Tech Asscn
4 Screening Screening Dipstick Hematuria studies from the late 1980 s Modern studies investigating markers Patients Dipstick + Bladder Ca PPV US Study ~ % 1.3% 8% UK Study ~600 17% 0.7% 5% Attempt identify higher risk groups Age, smoking, occupational exposure Steiner Lotan Greene Dipstick NMP22 Cytology UroVysion NMP22 Dipstick NMP22 Positive Test 31% 6% 5% 8% 6% 7% 0.5% Urothelial Ca 3% 3% 3% 3% 0.2% 0.3% 0.3% PPV 5% 9% 10% 7% 4% 4% 25% Messing Urol 1995 and Britton BMJ 1989 Steiner BJUI 2008, Lotan J Urol 2009, and Greene J Urol (supp) 2008 Diagnosis Public Health and Economic Impact Sensitivity/Specificity applicable same dz spectrum Urinary Tumor Markers PPV/NPV only applicable same dz prevalence DIAGNOSIS Future Directions Posterior Odds = Prior Odds X LR LR (+) = sensitivity / (1-specificity) LR (-) = (1-sensitivity) / specificity Prob = odds / (1+odds) Odds = prob / (1-prob) 4
5 Diagnosis Diagnosis Microscopic Hematuria -- Risk Bladder Ca ~3% Gross Hematuria -- Risk Bladder Ca ~20% Eliminate cystoscopy with negative test? Marker Sensitivity Specificity LR (-) Probability Hgb Dipstick 71% 67% % Cytology 44% 96% % BTA-STAT 69% 74% % BTA-TRAK 62% 74% % NMP22 68% 79% % ImmunoCyt 84% 75% % UroVysion 76% 85% % Eliminate cystoscopy with negative test? Marker Sensitivity Specificity LR (-) Probability Hgb Dipstick 71% 67% % Cytology 44% 96% % BTA-STAT 69% 74% % BTA-TRAK 62% 74% % NMP22 68% 79% % ImmunoCyt 84% 75% % UroVysion 76% 85% % Monitoring Monitoring LG Ta -- Recurrence 1 st yr is 37% (~9%/eval) HG Ta,T1,CIS -- Recurrence 1 st yr is 55% (~14%/eval) Eliminate cystoscopy with negative test? With negative cysto positive marker require biopsy? Marker Sensitivity Specificity LR (-) Probability Hgb Dipstick 8% 67% % Cytology 12% 96% % BTA-STAT 47% 74% % BTA-TRAK 63% 74% % NMP22 61% 79% % ImmunoCyt 80% 75% % UroVysion 45% 85% % Cysto sensitivity-85% specificity-70% LR(-) = 0.2. Post-cysto probability 3% Marker Sensitivity Specificity LR (+) Probability LR (-) Probability Hgb Dipstick 76% 67% 2.3 7% % Cytology 64% 96% % % NMP22 79% 79% % % ImmunoCyt 85% 75% % % UroVysion 91% 85% % % adapted from Lotan Urol 2003 and Lokeshwar Urol 2005 adapted from Lotan Urol 2003 Lokeshwar Urol
6 Cost-Effectiveness Public Health and Economic Impact Urinary Tumor Markers COST-EFFECTIVENESS Future Directions Lotan J Urol 2002 Cost-Effectiveness Cost-Effectiveness Closer to a true cost-effectiveness analysis 2010 Cytology and cystoscopy least effective strategy year life expectancy ~$30k per year of life saved Cysto+ImmunoCyt followed PDD TURBT dx and cysto follow-up most effective strategy year life expectancy ~$400k per year of life saved However, this still doesn t involve patient perspective Patient Perspective on Urinary Markers to Replace Cystoscopy 102 patients UMC, The Netherlands 89% prefer cysto over marker if sensitivity <90% Males, older patients, fewer prior cystos, fewer recurrences associated lower accepted sensitivity 200 patients MSKCC 75% required accuracy of >95% Males and >pain during procedure associated lower accepted accuracy Mowatt Health Tech Asscn 2010 Vriesema Urol 2000 and Yossepowitch J Urol
7 REFLEX TESTING Public Health and Economic Impact Urinary Tumor Markers FUTURE DIRECTIONS Lotan J Urol 2008 PROGNOSIS EARLY DETECTION IVT FAILURE Whitson BJUI 2009 Whitson Int Braz J Urol
8 Conclusions References Hard to find high risk group; Low PPV No prospective study survival benefit Microhematuria marker negative no cysto? Gross Hematuria little role for markers Low Risk ImmunoCyt? High Risk not significantly better cytology Lack of data particularly re: patient preferences 1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, CA: a cancer journal for clinicians 2009;59(4): Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. PharmacoEconomics 2003;21(18): Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Medical care 1995;33(8): Konety BR, Joyce GF, Wise M. Bladder and upper tract urothelial cancer. The Journal of urology 2007;177(5): Konety BR. Molecular markers in bladder cancer: a critical appraisal. Urologic oncology 2006;24(4): Mowatt G, Zhu S, Kilonzo M, et al. Systematic review of the clinical effectiveness and costeffectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health technology assessment (Winchester, England);14(4):1-331, iii-iv. 7. Messing EM, Young TB, Hunt VB, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 1995;45(3):387-96; discussion Britton JP, Dowell AC, Whelan P. Dipstick haematuria and bladder cancer in men over 60: results of a community study. BMJ (Clinical research ed 1989;299(6706): Steiner H, Bergmeister M, Verdorfer I, et al. Early results of bladder-cancer screening in a high-risk population of heavy smokers. BJU international 2008;102(3): Lotan Y, Elias K, Svatek RS, et al. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. The Journal of urology 2009;182(1):52-7; discussion Greene K. Results from the firefighters bladder cancer screening study. Journal of Urology 2008;179(4 (supp)):323. References (cont.) 12. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003;61(1):109-18; discussion Lokeshwar VB, Habuchi T, Grossman HB, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005;66(6 Suppl 1): Lotan Y, Roehrborn CG. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. The Journal of urology 2002;167(1): Vriesema JL, Poucki MH, Kiemeney LA, Witjes JA. Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: a utility analysis. Urology 2000;56(5): Yossepowitch O, Herr HW, Donat SM. Use of urinary biomarkers for bladder cancer surveillance: patient perspectives. The Journal of urology 2007;177(4): ; discussion Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Ashfaq R. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. The Journal of urology 2008;179(6): Whitson J, Berry A, Carroll P, Konety B. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU international 2009;104(3): Whitson JM, Berry AB, Carroll PR, Konety BR. UroVysion testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer. Int Braz J Urol 2009;35(6):664-70; discussion
MEDICAL POLICY SUBJECT: URINARY TUMOR MARKERS FOR BLADDER CANCER. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: URINARY TUMOR MARKERS FOR PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationShould We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis?
Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis? Yair Lotan, Robert S. Svatek, Arthur I. Sagalowsky Should We Screen? Prevalence 5 th most common cancer
More informationProtocol. Urinary Tumor Markers for Bladder Cancer
Protocol Urinary Tumor Markers for Bladder Cancer (20407) Medical Benefit Effective Date: 01/01/13 Next Review Date: 09/18 Preauthorization No Review Dates: 03/12, 09/12, 09/13, 09/14, 09/15, 09/16, 09/17
More informationCorporate Medical Policy
Corporate Medical Policy Urinary Tumor Markers for Bladder Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: urinary_tumor_markers_for_bladder_cancer 5/2011 11/2017 11/2018
More informationUrine Markers for Bladder Cancer. Peter Black, MD, FACS, FRCSC Khosrowshahi Family Chair Vancouver Prostate Centre University of British Columbia
Urine Markers for Bladder Cancer Peter Black, MD, FACS, FRCSC Khosrowshahi Family Chair Vancouver Prostate Centre University of British Columbia Disclosures Role Consultant/Speaker Grant Funding Clinical
More informationDecember 22, Earl Berman, MD Attn Medical Review Two Vantage Way Nashville, TN
December 22, 2016 Earl Berman, MD Attn Medical Review Two Vantage Way Nashville, TN 37228 cmd.inquiry@cgsadmin.com Re: Draft Local Coverage Determination - Bladder Tumor Markers (DL36975) Dear Dr. Berman:
More informationRelated Policies None
Medical Policy MP 2.04.07 BCBSA Ref. Policy: 2.04.07 Last Review: 06/22/2017 Effective Date: 06/22/2017 Section: Medicine End Date: 09/27/2018 Related Policies None DISCLAIMER Our medical policies are
More informationOriginal Policy Date
MP 2.04.05 Urinary Tumor Markers for Bladder Cancer Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to
More informationReviewer's report. Version:1Date:31 January Reviewer:IOANNIS LEOTSAKOS. Reviewer's report:
Reviewer's report Title:A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria
More informationUrinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance
Urinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance Policy Number: 2.04.07 Last Review: 12/2018 Origination: 12/2016 Next Review: 6/2019 Policy Blue Cross and Blue Shield of Kansas City
More informationCan Use the NMP22 BladderChek Decrease the Frequency of Cystoscopy in the Follow up of Patients with Bladder Carcinoma?
Original Article Int J Nephrol Urol, 2009; 1(1):51-55 Can Use the NMP22 BladderChek Decrease the Frequency of Cystoscopy in the Follow up of Patients with Bladder Carcinoma? Adel Allam 1*, Badawi Hathout
More informationTier 3: The effectiveness of urinary biomarker genotypes (Cxbladder Detect) in the investigation of haematuria in Primary Care
National Health Committee Tier 3: The effectiveness of urinary biomarker genotypes (Cxbladder Detect) in the investigation of haematuria in Primary Care National Health Committee (NHC) The National Health
More informationCosting report: Bladder cancer
Putting NICE guidance into practice Costing report: Bladder cancer Implementing the NICE guideline on bladder cancer (NG2) Published: February 2015 Updated September 2015 to update the unit cost of transurethral
More informationEffective Health Care Program
Comparative Effectiveness Review Number 153 Effective Health Care Program Emerging Approaches to Diagnosis and Treatment of Non Muscle-Invasive Bladder Cancer Executive Summary Background Bladder cancer
More information+ use molecular testing to help drive my patients treatment plans.
+ use molecular testing to help drive my patients treatment plans. Xpert Bladder Cancer Detection & Xpert Bladder Cancer Monitor In Vitro Diagnostic Medical Device Not all tests available in all countries.
More informationApplication of Urovision FISH testing for diagnosis of bladder cancer
Application of Urovision FISH testing for diagnosis of bladder cancer Eva M. Wojcik, MD Chair and Professor of Pathology and Urology Loyola University, Chicago, USA Bladder cancer - current status ~ 76,900
More informationUrinary Cytology. Spasenija Savic Prince Pathology, University Hospital Basel, Switzerland
Urinary Cytology Spasenija Savic Prince Pathology, University Hospital Basel, Switzerland Outline Pre-analytics The Paris System (TPS): Background Diagnostic categories Morphologic criteria for each category
More informationThe innovative aspect is that it detects bladder cancer based on the novel biomarker, minichromosome maintenance complex component 5 (MCM5).
pat hways ADXBLADDER for detecting bladder cancer Medtech innovation briefing Published: 12 April 2019 nice.org.uk/guidance/mib180 Summary The technology described in this briefing is ADXBLADDER. It is
More informationCYSVIEW. CONFIDENCE AT FIRST SIGHT
CYSVIEW. CONFIDENCE AT FIRST SIGHT Blue Light Cystoscopy with CYSVIEW Cysview Indication Cysview is an optical imaging agent indicated for use in the cystoscopic detection of non-muscle invasive papillary
More informationDipstick Urinalysis as a Test for Microhematuria and Occult Bladder Cancer
Bladder Cancer 3 (2017) 45 49 DOI 10.3233/BLC-160068 IOS Press Research Report 45 Dipstick Urinalysis as a Test for Microhematuria and Occult Bladder Cancer Richard S. Matulewicz a,b,, John Oliver DeLancey
More informationCorrespondence should be addressed to Tilman Todenhöfer;
Hindawi Disease Markers Volume 2018, Article ID 5823870, 5 pages https://doi.org/10.1155/2018/5823870 Research Article Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma:
More informationThe difference in cancer detection
in cancer detection 1 Introduction The difference in cancer detection Cxbladder Cxbladder is a non-invasive laboratory test for the detection of bladder cancer that gives you actionable results, which
More informationClinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer
International Journal of Urology (2011) 18, 439 443 doi: 10.1111/j.1442-2042.2011.02766.x Original Article: Clinical Investigationiju_2766 439..443 Clinical significance of immediate urine cytology after
More informationValidation of the Diagnostic Value of NMP22 W BladderChek W Test as a Marker for Bladder Cancer by Photodynamic Diagnosis
european urology 51 (2007) 403 408 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Validation of the Diagnostic Value of NMP22 W BladderChek W Test as a Marker
More informationClinical Study Point-of-Care Tests for Bladder Cancer: The Influencing Role of Hematuria
Advances in Urology Volume 2011, Article ID 937561, 5 pages doi:10.1155/2011/937561 Clinical Study Point-of-Care Tests for Bladder Cancer: The Influencing Role of Hematuria Joerg Hennenlotter, Severine
More informationControversies in the management of Non-muscle invasive bladder cancer
Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic
More informationAmerican Society of Cytopathology Core Curriculum in Molecular Biology
American Society of Cytopathology Core Curriculum in Molecular Biology American Society of Cytopathology Core Curriculum in Molecular Biology Chapter 6 Fluorescence in situ Hybridization (FISH) Principles
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title High-risk nonmuscle invasive bladder cancer: Definition and epidemiology Permalink https://escholarship.org/uc/item/11p2k07q Journal Current
More informationThe merits of cytology in the workup for upper tract urothelial carcinoma - a contemporary review of a perplexing issue
ORIGINAL ARTICLE Vol. 40 (4): 493-498, July. August, 2014 doi: 10.1590/S1677-5538.IBJU.2014.04.07 The merits of cytology in the workup for upper tract urothelial carcinoma - a contemporary review of a
More informationNMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland
NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.
More informationDiagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscleinvasive
Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscleinvasive bladder cancer David D Andrea*, Francesco Soria*,
More informationManagement of High-Risk Non-Muscle Invasive Bladder Cancer. Seth P. Lerner, MD, FACS
Management of High-Risk Non-Muscle Invasive Bladder Cancer Seth P. Lerner, MD, FACS Professor of Urology, Beth and Dave Swalm Chair in Urologic Oncology, Scott Department of Urology, Baylor College of
More informationIntroduction. Bladder cancer is the second most common genitourinary malignancy in the United States and the fifth most
The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride
More informationUroVysion Compared with Cytology and Quantitative Cytology in the Surveillance of Non Muscle-Invasive Bladder Cancer
european urology 51 (2007) 1275 1280 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer UroVysion Compared with Cytology and Quantitative Cytology in the Surveillance
More informationA novel urine cytology stain for the detection and monitoring of urothelial carcinoma
A novel urine cytology stain for the detection and monitoring of urothelial carcinoma Ofer Yossepovitch 1, Yoram Mor 2, Uri Lindner 3, Ofer Nativ 4, Ofer Gofrit 5, Ilan Leibovitch 6, Haim Matzkin 7, Ami
More informationBladder Cancer Early Detection, Diagnosis, and Staging
Bladder Cancer Early Detection, Diagnosis, and Staging Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can be
More informationAfterword: The Paris System for Reporting Urinary Cytology
Afterword: The Paris System for Reporting Urinary Cytology Dorothy L. Rosenthal, Eva M. Wojcik, and Daniel F.I. Kurtycz The primary goal of The Paris System Working Group was standardizing the terminology
More informationStaging and Grading Last Updated Friday, 14 November 2008
Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty
More informationEXCLUSION CRITERIA ENHANCE THE SPECIFICITY AND POSITIVE PREDICTIVE VALUE OF NMP22* AND BTA STAT
0022-5347/99/1621-0053/0 THE JOURNAL OF UROLOGY Vol. 162, 53 57, July 1999 Copyright 1999 by AMERICAN UROLOGICAL ASSOCIATION, INC. Printed in U.S.A. EXCLUSION CRITERIA ENHANCE THE SPECIFICITY AND POSITIVE
More information10/23/2012 CASE STUDIES: RENAL AND UROLOGIC IMPAIRMENTS. 1) Are there any clues from this history that suggest a particular diagnosis?
Case # 1 An underwriter enters your office, hands you a sheet of paper, and asks What do you think? Can we make an offer? You look at the paper and see it s lab results on a 60 year male looking for $500,000
More informationGUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationPanel: A Case-based Approach to the Management of Bladder Cancer
Panel: A Case-based Approach to the Management of Bladder Cancer ~ Moderator: Robert Donohue, MD Panel: David C. Beyer, MD E. David Crawford, MD Donald L. Lamm, MD Paul D. Maroni, MD TCC Cases Robert E.
More informationThe Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis
Bladder Cancer 2 (2016) 273 278 DOI 10.3233/BLC-160048 IOS Press Research Report 273 The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis Ashish
More informationBladder Cancer in Primary Care. Dr Penny Kehagioglou Consultant Clinical Oncologist
Bladder Cancer in Primary Care Dr Penny Kehagioglou Consultant Clinical Oncologist Objectives Patient presentation in primary care Investigating bladder cancer Management of bladder cancer Differential
More informationIL-8 as a urinary biomarker for the detection of bladder cancer
Urquidi et al. BMC Urology 2012, 12:12 RESEARCH ARTICLE Open Access IL-8 as a urinary biomarker for the detection of bladder cancer Virginia Urquidi 1, Myron Chang 2, Yunfeng Dai 2, Jeongsoon Kim 1, Edward
More informationClinical Utility of Fluorescent in situ Hybridization for the Surveillance of Bladder Cancer Patients Treated with Bacillus Calmette-Guérin Therapy
european urology 52 (2007) 752 759 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Clinical Utility of Fluorescent in situ Hybridization for the Surveillance
More informationYavuz Dodurga 1, ÇIğIr Biray AvcI 2, Sunde YIlmaz 2, Oktay NazlI 3, Özgür Çoğulu 4, Tufan Cankaya 5, Cumhur Gündüz 2. Introduction
Wspolczesna Onkol 2013; 18 (2): DOI: 10.5114/wo.2013.34619 Original paper Bladder cancer is the fourth most common cancer in men and the fifth most common cancer worldwide. UroVysion FISH has high sensitivity
More informationHaematuria and Modern Bladder Cancer Treatment
Haematuria and Modern Bladder Cancer Treatment Mr Nikhil Vasdev MBBS MRCS MCh(Urol) FRCS(Urol) RCSEng/BAUS Robotic Fellowship Accredited and Trained Consultant Urological and Robotic Surgeon Hertfordshire
More informationIssues in the Management of High Risk Superficial Bladder Cancer
Issues in the Management of High Risk Superficial Bladder Cancer MICHAEL A.S. JEWETT DIVISION OF UROLOGY, DEPARTMENT OF SURGICAL ONCOLOGY, PRINCESS MARGARET HOSPITAL & THE UNIVERSITY OF TORONTO 1 Carcinoma
More informationBladder Cancer Canada November 21st, Bladder Cancer 2018: A brighter light at the end of the cystoscope
Bladder Cancer Canada November 21st, 2018 Bladder Cancer 2018: A brighter light at the end of the cystoscope Chris Morash MD FRCSC Associate Professor, University of Ottawa Head, Urological Oncology Bladder
More informationThe application of cytology in urological diseases
Voided urine cytology The application of cytology in urological diseases Dr Ashish Chandra FRCPath DipRCPath (Cytol) Guy s & St Thomas NHSfT London Detection of high grade urothelial carcinoma Monitoring
More informationUpdate on Haematuria and Bladder Cancer
Update on Haematuria and Bladder Cancer Hugh Mostafid FRCS(urol) FEBU Consultant Urologist, Royal Surrey County Hospital and Honorary Senior Lecturer, University of Surrey Guildford None Declarations Recent
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationBladder cancer - suspected
Background information Information resources for patients and carers Updates to this care map Bladder cancer - clinical presentation History Examination Consider differential diagnoses Clinical indications
More informationHey Doc, there s blood in my urine Evaluation of hematuria. Christian S. Kuhr, MD FACS May 4, 2018
Hey Doc, there s blood in my urine Evaluation of hematuria Christian S. Kuhr, MD FACS May 4, 2018 Objectives Understand the algorithm for hematuria evaluation Know the differential diagnosis for hematuria
More informationBladder Cancer Diagnostic Tests
ISSN (Online): 1694-0784 ISSN (Print): 1694-0814 18 Bladder Cancer Diagstic Tests Shefali Jasra,Rishi Gupta, Shruti Mittal Lingayas Institute of Techlogy and Management Lingayas Institute of Techlogy and
More informationThe importance of molecular tumor markers for bladder cancer
Turkish Journal of Cancer Volume 33, No. 4, 2003 171 The importance of molecular tumor markers for bladder cancer SERDAR ARISAN Şişli Etfal Research and Training Hospital, 1 st Urology Clinic, Istanbul
More informationHaematuria and Bladder Cancer
Haematuria and Bladder Cancer Dr Pardeep Kumar Consultant Urological Surgeon Haematuria 3 Haematuria Macroscopic vs Microscopic Painful vs Painless Concurrent abdo pain/urinary symptoms Previous testing?
More informationTUR-BT : transurethral resection of bladder tumor. 95 transitional cell carcinoma : Cytokeratin ; CK 8 11nm kD CK 1 8
Clinical evaluation of total amount of Urinary cytokeratin 8 and cytokeratin 18 measurement for detection of transitional cell carcinoma of the bladder. Kyoko ARAI Mikihiko HONDA Ken-Ichiro YOSHIDA 95transitional
More informationImmunoCyt test compared to cytology in the diagnosis of bladder cancer: A meta-analysis
ONCOLOGY LETTERS 12: 83-88, 2016 ImmunoCyt test compared to cytology in the diagnosis of bladder cancer: A meta-analysis HOUGUANG HE, CONGHUI HAN, LIN HAO and GUANGHUI ZANG The Affiliated Xuzhou Hospital
More informationOptimising the management of non-muscle invasive bladder cancer from diagnosis to cure. Dr Richard Savdie Uro-Oncology Fellow BSc MBBS FRACS
Optimising the management of non-muscle invasive bladder cancer from diagnosis to cure Dr Richard Savdie Uro-Oncology Fellow BSc MBBS FRACS Objectives 1. Explore best practice diagnostic techniques 2.
More informationAsian J Androl 2007; 9 (5): DOI: /j x
DOI: 10.1111/j.1745-7262.2007.00218.x www.asiaandro.com. Clinical Experience. Comparisons of voided urine cytology, nuclear matrix protein-22 and bladder tumor associated antigen tests for bladder cancer
More informationIntroduction. Phil Hyun Song, MD, PhD 1 Seok Cho, MD 2 Young Hwii Ko, MD, PhD 1. pissn , eissn
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2016;48(1):273-280 Original Article http://dx.doi.org/10.4143/crt.2014.190 Open Access Decision Based on Narrow Band Imaging Cystoscopy without a Referential
More informationUrinary Cytology. Spasenija Savic Prince, MD Pathology, University Hospital Basel, Switzerland
Urinary Cytology Spasenija Savic Prince, MD Pathology, University Hospital Basel, Switzerland Outline Pre-analytics The Paris System (TPS): Background Diagnostic categories Morphologic criteria for each
More informationModified UroVysion scoring criteria increase the urothelial carcinoma detection rate in case of equivocal. urinary cytology
Modified UroVysion scoring criteria increase the urothelial carcinoma detection rate in case of equivocal urinary cytology Clément J.R. Huysentruyt, Marcella Baldewijns, Andrea Rüland, Ronald Tonk, Peter
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationGuidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS)
Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt European Association of Urology 2011 TABLE OF CONTENTS
More informationDiagnosis and classification
Patient Information English 2 Diagnosis and classification The underlined terms are listed in the glossary. Signs and symptoms Blood in the urine is the most common symptom when a bladder tumour is present.
More informationGuidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationCystoscopy in children presenting with hematuria should not be overlooked
Ped Urol Case Rep 2015; 2(3):7-11 DOI: 10.14534/PUCR.2015310303 PUCR Ped Urol Case Rep PEDIATRIC UROLOGY CASE REPORTS ISSN: 2148 2969 Journal homepage: http://www.pediatricurologycasereports.com Cystoscopy
More informationOriginal Article Urinary BLCA-4 is Highly Specific for Detection of Bladder Cancer in Chinese Han Population and Is Related to Tumour Invasiveness
Original Article Urinary BLCA-4 is Highly Specific for Detection of Bladder Cancer in Chinese Han Population and Is Related to Tumour Invasiveness (bladder cancer / BLCA-4 / Chinese / Han nationality)
More informationDiagnosis & Treatment of Non- Muscle Invasive Bladder Cancer: AUA/SUO Guidelines
Diagnosis & Treatment of Non- Muscle Invasive Bladder Cancer: AUA/SUO Guidelines Sam S. Chang, MD, MBA Patricia & Rodes Hart Chair Professor of Urologic Surgery & Oncology Vanderbilt University Medical
More informationH(a)ematuria. FX Keeley Consultant Urologist Bristol Urological Institute
H(a)ematuria FX Keeley Consultant Urologist Bristol Urological Institute From Philadelphia to Bristol, England Southmead Hospital, 1916 Southmead Hospital, 2013 Southmead Hospital, 2014 H(a)ematuria Blood
More information3.1 Investigations for Patients Presenting with Haematuria Table 1
3.1 Investigations for Patients Presenting with Haematuria Table 1 Patients at risk of bacterial endocarditis should be given antibiotic prophylaxis as per local guidelines. Patients with heart valve replacements
More informationMODULE 5: HEMATURIA LEARNING OBJECTIVES DEFINITION. KEY WORDS: Hematuria, Cystoscopy, Urine Cytology, UTI, bladder cancer
MODULE 5: HEMATURIA KEY WORDS: Hematuria, Cystoscopy, Urine Cytology, UTI, bladder cancer LEARNING OBJECTIVES At the end of this clerkship, the learner will be able to: 1. Define microscopic hematuria.
More informationConversations: Let s Talk About Bladder Cancer
Understanding Biomarkers Matt Gaslky, MD, Professor of Medicine Icahn School of Medicine at Mount Sinai Piyush Agarwal, MD, Head, Bladder Cancer Section Urological Oncology Branch, National Cancer Institute
More informationClinical Policy Title: Enhanced cystoscopy for bladder cancer
Clinical Policy Title: Enhanced cystoscopy for bladder cancer Clinical Policy Number: 13.01.04 Effective Date: April 1, 2017 Initial Review Date: February 15, 2017 Most Recent Review Date: March 15, 2017
More informationBladder cancer is the fourth most common cancer
ADULT UROLOGY SENSITIVITY AND SPECIFICITY OF COMMONLY AVAILABLE BLADDER TUMOR MARKERS VERSUS CYTOLOGY: RESULTS OF A COMPREHENSIVE LITERATURE REVIEW AND META-ANALYSES YAIR LOTAN AND CLAUS G. ROEHRBORN ABSTRACT
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationBLADDER CANCER: PATIENT INFORMATION
BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,
More informationReviewing Immunotherapy for Bladder Carcinoma In Situ
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
More informationCitation International journal of urology (2. Right which has been published in final f
Title Novel constant-pressure irrigation of renal pelvic tumors after ipsila Nakamura, Kenji; Terada, Naoki; Sug Author(s) Toshinori; Matsui, Yoshiyuki; Imamu Kazutoshi; Kamba, Tomomi; Yoshimura Citation
More informationA Personal History NIH CWRU U of TN U of Miami Animal Model for Bladder Cancer Carcinogen induced FANFT Three Models Primary tumors individual tumors, simulates clinical scenario of locally advanced cancer
More informationCitation for published version (APA): Cauberg, E. C. C. (2011). Advancements in diagnostic imaging for urothelial carcinoma
UvADARE (Digital Academic Repository) Advancements in diagnostic imaging for urothelial carcinoma Cauberg, E.C.C. Link to publication Citation for published version (APA): Cauberg, E. C. C. (2011). Advancements
More informationASYMPTOMATIC MICROSCOPIC HEMATURIA IN WOMEN JOLYN HILL, MD ASSISTANT PROFESSOR, CLINICAL UROGYNECOLOGY FEBRUARY14, 2017
ASYMPTOMATIC MICROSCOPIC HEMATURIA IN WOMEN JOLYN HILL, MD ASSISTANT PROFESSOR, CLINICAL UROGYNECOLOGY FEBRUARY14, 2017 DISCLOSURES No financial disclosures Urogynecologist via Ob/Gyn pathway ASYMPTOMATIC
More informationCase Studies in Renal & Urologic Impairments
Case Studies in Renal & Urologic Impairments Karen Blackstone MD, DBIM Chief Medical Director / Vice President AAIM October 2015 Normal Lab Values for Case #1 Serum Creatinine Female 0.6 1.3 mg/dl (53-115
More informationMEDitorial March Bladder Cancer
MEDitorial March 2010 Bladder Cancer Last month, my article addressed the issue of blood in the urine ( hematuria ). A concerning cause of hematuria is bladder cancer, a variably malignant tumor starting
More informationThe Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary Study
The Journal of International Medical Research 2009; 37: 1823 1830 The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary
More informationLong-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression
BJU International (2), 85, 824±828 Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression K. ZIEGER, H. WOLF, P.R. OLSEN* and K. HéJGAARD{ Department of Urology, Aarhus
More informationManagement of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.
Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationOriginal article J Bas Res Med Sci 2016; 3(4):28-33.
Diagnostic value of a combined C-reactive protein and haptoglobin test in new cases of upper tract urothelial carcinoma Hossein Beig-Mohammadi 1, Nahid Masoudian 1, Ali Tabibi 2, Abdolamir Allameh 3* 1.
More informationACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI
USCAP GU Specialty Conference Case 3 March 2016 L. Priya Kunju, M.D. University of Michigan Health System Ann Arbor, MI University of Michigan Health System ACCME/Disclosures The USCAP requires that anyone
More informationA NOVEL URINE CYTOLOGY STAIN FOR THE DETECTION AND MONITORING OF UROTHELIAL CARCINOMA. Running head: A Novel Stain For The Detection Of Bladder Cancer
A NOVEL URINE CYTOLOGY STAIN FOR THE DETECTION AND MONITORING OF UROTHELIAL CARCINOMA Authors Noa Davis 1, Yoram Mor 4, Pavel Idelevich 1, Dov Terkieltaub 1, Vivi Ziv 1, Adi Elkeles 1, Sylvia Lew 2, Elimelech
More informationBas W.G. van Rhijn, M.D., Ph.D., F.E.B.U.*
Urologic Oncology: Seminars and Original Investigations 30 (2012) 518 523 Seminar article Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer Bas W.G. van Rhijn,
More informationLet us know how access to this document benefits you
Thomas Jefferson University Jefferson Digital Commons Department of Urology Faculty Papers Department of Urology 7-2014 Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined
More informationNon-Muscle Invasive Bladder Cancer BCG Failures: University of Iowa Hospitals and Clinics Experience. Paul Gellhaus Assistant Clinical Professor
Non-Muscle Invasive Bladder Cancer BCG Failures: University of Iowa Hospitals and Clinics Experience Paul Gellhaus Assistant Clinical Professor Iowa??? none Disclosures Caveats Dr. Michael O Donnell
More informationSymptoms, Diagnosis and Classification
Patient Information English 2 Symptoms, Diagnosis and Classification The underlined terms are listed in the glossary. Signs and symptoms Blood in the urine is the most common symptom when a bladder tumour
More informationEAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER
EU GUIDELINES ON NON-MUSLE INVSIVE (TaT1, IS) LDDER NER (Limited text update March 2017) M. abjuk (hair), M. urger (Vice-hair), E. ompérat, P. Gontero,.H. Mostafid, J. Palou,.W.G. van Rhijn, M. Rouprêt,
More informationCase Presentation 58 year old male with recent history of hematuria, for which he underwent cystoscopy. A 1.5 cm papillary tumor was found in the left lateral wall of the bladder. Pictures of case Case
More informationFrequency and predictors of recurrence of bladder tumour on first check cystoscopy a tertiary care hospital experience
2nd Annual Surgical Meeting 2016 S-125 UROLOGY ORIGINAL ARTICLE Frequency and predictors of recurrence of bladder tumour on first check cystoscopy a tertiary care hospital experience Muhammad Farhan, Syed
More information